This Week in Science

In Science Translational Medicine this week, a team from Northwestern University reports on the use of a novel nanoparticles to deliver therapeutic RNAi agents into brain tumors in mice. Called spherical nucleic acids, the nanoparticles are essentially gold cores surrounded by a dense shell of highly oriented DNA or RNA. In the study, the researchers were able to use SNAs to carry siRNAs against a key oncogene into tumors in mouse models, where they knocked down their target and killed off cancer cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.